Trending News Today: Breast Cancer Drug May Work Just as Well with Briefer Treatment

A new study finds that treating breast cancer with the drug Herceptin may work just as well with a briefer treatment regimen and reduce adverse effects, NPR reported. In a study of more than 4000 women, the study authors determined that women with early-stage HER2-positive breast cancer did just as well with 6 months of treatment with Herceptin as did women who received a 12-month treatment course. According to the article, benefits of shorter treatment would be reduced costs and fewer adverse effects, such as less damage to the heart.
Vermont has become the first US state to permit the importation of prescription drugs from Canada, according to The Hill. Proponents of the law believe it will help fight rising drug prices, the article reported. Eight states proposed similar legislation this year, but Vermont’s is the first to be signed into law, according to the article. The law must still be certified by the Department of Health and Human Services.
Less than 2% of eligible current and former smokers have sought free lung scans, the Associated Press reported. The scans, which typically cost $100 to $250, are free for those who meet the criteria, but individuals must have a special appointment to discuss risks and benefits with a physician, the article reported. Experts indicated that possible explanations as to why screening rates are so low include worries about false alarms and follow-up tests, a physician visit to get the scans covered, fear and denial of the consequences of smoking, and little knowledge that screening exists. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Top news of the day across the health care landscape.
Pembrolizumab (Keytruda) plus axitinib (Inlyta) was evaluated in a clinical trial of patients with clear-cell metastatic renal cell carcinoma.
Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.